The waiting room of a community oncology clinic doesn’t smell like medicine. It smells like industrial carpet cleaner and the faint, metallic tang of anxiety. For a patient sitting there, holding a folder full of scans that look like topographical maps of a war zone, words are more than just information. They are life rafts. When a doctor or a headline mentions a new treatment, the heart does something dangerous. It hopes.
That hope is the most valuable commodity in the world. It is also the most fragile.
In the high-stakes theater of American biotechnology, few figures loom larger than Dr. Patrick Soon-Shiong. He is a man of immense intellect, a surgeon who became a billionaire by reimagining how we fight disease. He owns the Los Angeles Times. He has been called the richest doctor in the world. But recently, the Food and Drug Administration (FDA) had to step in because the story being told about one of his company’s cancer drugs didn't match the reality of the data.
The conflict centers on a drug called Anktiva. Developed by Soon-Shiong’s company, ImmunityBio, it was approved to treat a specific, stubborn form of bladder cancer. On paper, it was a victory. In practice, the way the company talked about that victory crossed a line that the federal government spent decades drawing in the sand.
The Weight of a Word
The FDA’s Office of Prescription Drug Promotion doesn't usually get emotional. They speak in the clipped, sterilized language of regulatory compliance. Yet, their recent warning letter to ImmunityBio carries a heavy subtext. They flagged a video featuring Soon-Shiong himself, along with company presentations, for making claims that were, in their view, "false or misleading."
Specifically, the company suggested that Anktiva was a "breakthrough" that offered "superiority" over existing treatments. To a casual listener, these sound like synonyms for "better." In the world of oncology, they are legal terms of art.
Consider a hypothetical patient named Elena. Elena has non-muscle invasive bladder cancer. She has already tried the standard treatments. They failed. She is looking for the next thing, the "miracle" that will keep her out of surgery. When she hears a world-renowned scientist describe a drug as a total paradigm shift—a word often used in these circles despite its hollowness—she isn't thinking about p-values or confidence intervals. She is thinking about seeing her grandson graduate.
The FDA’s problem was simple: ImmunityBio hadn't actually conducted the head-to-head clinical trials necessary to prove Anktiva was better than the competition. They were comparing their results to historical data from other studies. In science, that is like comparing a sprinter’s time in the 1920s to a modern athlete and claiming the modern one is faster because of their shoes. There are too many variables. The track is different. The wind has changed.
The Optics of the Outlier
Soon-Shiong has always been a disruptor. He built his fortune on Abraxane, a drug that redesigned how chemotherapy hits a tumor. He is a man who believes in the "Moonshot," a term he championed to describe a coordinated strike against cancer using the body’s own immune system.
But disruption has a shadow side.
In the flagged video, the FDA noted that the company omitted crucial risk information. Every drug is a trade-off. You accept the poison to kill the invader. Anktiva comes with a list of side effects—serious ones. When a company highlights the "complete response" rate but whispers the part about the painful complications or the frequency of those responses, the scales of informed consent start to tip.
The FDA pointed out that the promotional materials downplayed the fact that the drug's efficacy was measured in a very specific, limited group of patients. It wasn't a universal solvent for cancer. It was a tool for a specific job. By broadening the narrative, the company wasn't just marketing; they were potentially distorting the clinical decisions of doctors and the expectations of the dying.
The Cost of the Hype Cycle
Why does a billionaire with everything to lose take these risks? The answer lies in the brutal economy of biotech. The gap between a drug’s approval and its commercial success is a valley of death. Investors want to see rapid adoption. They want to see a "blockbuster."
When a drug enters the market, it isn't just competing against cancer cells. It is competing for the attention of insurance companies and the limited time of oncologists. In that environment, nuance is often the first casualty. If you describe your drug as "one of several options for a niche population," the stock price might stagnate. If you describe it as the "cure we’ve been waiting for," the world listens.
But science is not a stump speech. It is a slow, agonizing process of proving yourself wrong until only the truth remains.
The FDA’s warning isn't just a slap on the wrist for a wealthy executive. It is a protective barrier for the Elenas of the world. It exists to ensure that when a patient sits in that chair, smelling the carpet cleaner and the fear, the words they are reading are anchored in stone, not spun from gold.
The Invisible Stakes
We live in an era where the line between "founder" and "prophet" has blurred. We want our innovators to be geniuses who see what we cannot. Soon-Shiong fits that mold perfectly. He is charismatic, tireless, and genuinely brilliant. But the human element of medicine requires a different kind of brilliance: the humility to admit what we don't know yet.
The data for Anktiva is promising. That is the tragedy of the situation. The drug may very well be a vital tool in the oncologist’s arsenal. But by overreaching, by polishing the truth until it reflected only what they wanted to see, the company invited a shadow of doubt over the very work they spent years perfecting.
When a regulatory agency flags a drug's marketing, it sends a ripple through the entire medical community. Doctors become more cautious. Patients become more skeptical. The "trust" that serves as the foundation of the patient-provider relationship begins to crack.
The invisible stakes are the thousands of conversations happening in exam rooms across the country. In those rooms, the "billionaire" doesn't matter. The "biotech" doesn't matter. Only the truth of the molecule matters.
The Mirror
If you look at the promotional video that started this, you see a man who clearly believes in his mission. Soon-Shiong doesn't look like a villain; he looks like a believer. And that is perhaps the most dangerous thing of all. When the person at the top believes their own hype so much that they find the FDA's rules to be mere "suggestions" or "bureaucratic hurdles," the system breaks.
The rules of drug promotion aren't there to stifle innovation. They are there to ensure that innovation doesn't become exploitation. Cancer is a thief. It steals time, money, and identity. The last thing a cancer patient needs is to have their hope stolen by a misleading chart or an exaggerated adjective.
The FDA has given ImmunityBio a deadline to correct the record. They will have to issue "truthful, non-misleading, and complete" information to the same audiences they reached with the original claims. They will have to look in the mirror and reconcile the scientist with the salesman.
In the end, the story of Anktiva isn't about a drug at all. It is about the language of life and death. It is about the responsibility that comes with holding a "cure" in your hands. Because for the person in the waiting room, a word is never just a word. It is the difference between a peaceful night and a devastating realization.
The billionaire will be fine. The company will likely pivot. But the ghost of the cure—the one that was promised to be better than everything else without the proof to back it up—will linger in the halls of the FDA for a long time to come.
Truth is the only medicine that doesn't have a side effect.
